Migraspirin 500 mg 12 effervescent tablets
100% secure payment
Shipping and Postage
Deliveries within 24-48 working hours for products available in stock. Shipping from €3.99 and free on purchases >€40, for PT Continental. Returns? Find out more here .
Migraspirina® contains acetylsalicylic acid, the active substance in Aspirin®, which relieves headaches associated with migraine. Suitable for people over 18 years of age.
- Dissolve 2 effervescent tablets in a glass of water and drink the entire contents of the glass. The tablets dissolve quickly and are quickly absorbed in the gastrointestinal tract for fast pain relief.
How to Use
Each pack of Migraspirina® contains 12 effervescent tablets. This medicine is administered orally. Administration depends on the appearance of symptoms and should be stopped when they disappear.
Recommended dose of Migraspirina®
Adults : 2 effervescent tablets (1000 mg). Maximum daily dose: 6 effervescent tablets (3 g). Dissolve the two effervescent tablets in a glass of water and drink the entire contents of the glass. Single doses can be taken at 4-8 hour intervals, up to three times a day if necessary.
The maximum daily dose should not be exceeded.
Migraspirin should not be taken for more than 3 consecutive days without consulting a doctor. If migraine attacks are frequent, if their frequency increases or if symptoms persist, a doctor should be consulted and an alternative treatment should be considered.
Migraspirina® contains 500 mg of acetylsalicylic acid. Indicated for the symptomatic relief of headaches associated with migraine. 2 effervescent tablets (single dose of 1000 mg), maximum 8 effervescent tablets per day with an interval of 4 - 8 hours. Contraindicated: Acute gastrointestinal ulcer; Hemorrhagic diathesis; Hypersensitivity to acetylsalicylic acid, other salicylates or any of the excipients of the drug; History of asthma induced by the administration of salicylates or substances with similar action, in particular non-steroidal anti-inflammatory drugs; Severe hepatic insufficiency; Severe renal insufficiency; Severe heart failure; Association with methotrexate doses equal to or greater than 15 mg/week; Last trimester of pregnancy Non-prescription and non-reimbursed drug. Read the package leaflet carefully. If you have any questions or symptoms persist, consult your doctor or pharmacist. For further information, see the package leaflet here .